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Cardiovascular disease (CVD) is the leading cause of death worldwide. The human body is 38 
populated by a diverse community of microbes, dominated by bacteria, but also including 39 
viruses and fungi. The largest and most complex of these communities is located in the 40 
gastrointestinal system and with their associated genome, are known as the gut microbiome. 41 
Gut microbiome perturbations and related dysbiosis have been implicated in the progression 42 
and pathogenesis of CVD, including atherosclerosis, hypertension and heart failure. Although 43 
there have been advances in the characterisation and analysis of the gut microbiota and 44 
associated bacterial metabolites, the exact mechanisms through which they exert their action 45 
is not well understood. This review will focus on the role of the gut microbiome and 46 
associated functional components in the development and progression of atherosclerosis. 47 
Potential treatments to alter the gut microbiome to prevent or treat atherosclerosis and CVD 48 
are also discussed.  49 
 50 
 51 
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List of abbreviations: 56 
 57 
AAA: abdominal aortic aneurysm 58 
ACS: acute coronary syndrome  59 
AMPK: adenosine monophosphate-activated protein kinase 60 
ApoE-/- : apolipoprotein E knockout 61 
BA: bile acid 62 
CAD: coronary artery disease  63 
CLA: conjugated linoleic acids 64 
CVD: cardiovascular disease 65 
FOS: fructooligosaccharides 66 
FXR: Farnesoid X receptor 67 
GPR: G protein-coupled receptor  68 
LDL-C: low density lipoprotein-c 69 
PAD: peripheral arterial disease 70 
SCFA: short chain fatty acid 71 
TGR: Takeda G protein coupled receptor  72 
TLR: toll-like receptors  73 
TMA: trimethylamine 74 
TMAO: trimethylamine-N- oxide 75 
16S rRNA: 16S ribosomal ribonucleic acid 76 
  77 





Cardiovascular disease (CVD) is the leading cause of death and disability globally (60). The 80 
human gut is populated by a diverse and complex community of bacteria, viruses, fungi and 81 
protozoa, which along with their genome, are collectively known as the gut microbiome (90). 82 
An alteration in gut microbiome composition and linked functionality is known as microbial 83 
dysbiosis. Studies have shown that gut microbiota interact with the host, contributing to host 84 
health and disease status. Although there is a large interindividual variation in terms of 85 
microbial composition, healthy individuals share core functional capabilities (146). However, 86 
several disease states, including CVD, are associated with microbial dysbiosis (78). There is 87 
increasing evidence in CVD demonstrating an alteration in diversity and composition of the 88 
gut microbiome and its associated metabolites which may influence the pathogenesis and 89 
progression of diseases such as atherosclerosis [acute coronary syndrome (ACS) and stroke], 90 
heart failure and hypertension. The complex host-microbiome interaction influences the 91 
synthesis and release of several metabolites including trimethylamine-N-oxide (TMAO), bile 92 
acids (BA) and short chain fatty acids (SCFA), which impact host homeostasis (139). While 93 
recent advances in genomic and metabolomics have allowed the accurate characterisation and 94 
quantification of these microbes and their metabolites, the exact mechanisms of their action 95 
remain unclear. Interventions targeting the microbiome could provide new avenues for the 96 
management and treatment of CVD patients (138). In this review we will discuss the 97 
development and progression of atherosclerosis, the contribution of the microbiota, 98 
specifically the gut bacteria, and the potential for targeting the microbiome and its associated 99 
components as novel therapeutic options. 100 
 101 
The gut microbiome  102 
 103 
A complex and dynamic community of microbes live in the human gastrointestinal tract, a 104 
nutrient rich microenvironment conducive for the growth of microorganisms. (146). There is 105 
a dominance of bacteria in this environment belonging to five main phyla: Firmicutes, 106 
Bacteroidetes, Actinobacteria, Proteobacteria and Verrucomicrobia (Figure 1) (177). There is 107 
large interindividual variation in the composition, diversity and abundance of bacteria and 108 
microbes, predominantly due to host genome factors as well as environmental parameters like 109 
lifestyle, diet, hygiene, health, medication such as antibiotics and the use of prebiotics and 110 
probiotics (18). There is a symbiotic relationship between the host and the microbiota, 111 
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developing from birth through to adulthood (76). The symbiotic relationship of the 112 
microbiome and the host promote the growth of beneficial commensal bacteria while 113 
inhibiting the overgrowth of pathogenic ones (102). 114 
 115 
The normal physiological functions of the gut microbiome include fermentation of 116 
indigestible dietary substances (87), synthesis of certain vitamins (122), energy metabolism 117 
via SCFA production (13) and the regulation of the intestinal epithelial mucosal barrier (73). 118 
If disrupted, this barrier will result in ‘leakage’ allowing bacterial translocation and an 119 
increase in exposure to bacterial derived products such as  circulating endotoxins. 120 
 121 
The gut microbiome has a very diverse role and can have distal effects in the body. There is a 122 
complex interplay between the gut microbiome and the health and function of the host via 123 
production and release of important metabolites including SCFA, BAs and TMAO as well as 124 
influencing various host metabolic pathways (139). These metabolites can be absorbed into 125 
the bloodstream via the intestinal epithelium, thus influencing the function of several distal 126 
organs and body systems (127).  127 
 128 
Atherosclerosis   129 
 130 
Atherosclerosis is a chronic inflammatory condition resulting from initial endothelial injury 131 
followed by lipid build-up and plaque formation in the arteries. Risk factors for 132 
atherosclerosis include hypercholesterolaemia, hypertension, diabetes mellitus, obesity, and a 133 
sedentary lifestyle (113). Cellular events that contribute to the initiation and progression of 134 
atherosclerosis involve; lipid migration to the inner layer of the arterial wall – the 135 
endothelium, adhesion of circulating monocytes and lymphocytes to the endothelial cells, 136 
migration of monocytes into the sub-endothelial space and acquiring macrophage 137 
characteristics and converting into foam cells (113). Low density lipoprotein (LDL) particles 138 
undergo modification, primarily through oxidation, becoming strong chemo attractants (113). 139 
These processes, which involve cell adhesion, migration, differentiation, further proliferation 140 
and interaction with the extra cellular matrix, are controlled and regulated by a cascade of 141 
cytokines and growth regulatory peptides and ultimately lead to the accumulation of 142 
cholesterol and the formation of fatty streaks (113). Vascular smooth muscle cells also 143 
migrate to the endothelium and proliferate, with additional accumulation of macrophages, 144 
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modified LDL and inflammatory cells, together forming the atherosclerotic plaque (11). The 145 
plaque consists of various cells (endothelial cells, foam cells, macrophages and leukocytes), 146 
accumulated lipids (cholesterol, triglycerides), calcified regions and a necrotic core (113).  147 
Vascular dysfunction and hypertension contribute to vessel damage via mechanisms 148 
involving an increase in inflammation and LDL, causing plaque formation and build up in 149 
arterial walls progressing to atherosclerosis (11). Atherosclerosis progresses to various 150 
cardiovascular diseases such as ACS, stroke, AAA and ultimately heart failure.  151 
 152 
Microbiota and their metabolites profoundly modulate the progression of atherosclerosis, the 153 
most common cause of ACS, stroke and peripheral vascular disease (Figure 2) (74). 154 
However, despite this, the mechanisms of action as to how the gut microbiota contribute to 155 
atherosclerosis remain to be elucidated. Recent reviews have highlighted the potential role of 156 
dysbiosis in several disease states, including atherosclerosis, heart failure, hypertension and 157 
diabetes mellitus (3, 145). In these states the gut bacteria diversity, composition and 158 
associated metabolic functions can change, leading to disruption of vital physiological 159 
processes, including inflammation, lipid metabolism, bacterial translocation and glucose 160 
homeostasis which may all contribute to disease development and progression.  161 
 162 
Changes in the microbiome composition may also contribute to the development and 163 
progression of CVD, with alterations in the ratio of  the key phyla of Firmicutes to 164 
Bacteroidetes proposed as a potential risk factor of CVD (20, 32, 135). Similarly, there is a 165 
correlation between various gut microbiome metabolite levels, including TMAO, SCFA and 166 
BA and the pathogenesis of CVD. Finally, risk factors and associated symptoms of CVD may 167 
cause further microbial dysbiosis, including accumulation of toxic metabolites (such as 168 
TMAO) and pathogenic bacterial species (73, 146, 177). 169 
 170 
In the gut, symptomatic atherosclerotic patients had a greater abundance of Collinsella 171 
compared to healthy controls (48, 68). However, several of these studies were limited by their 172 
small sample sizes (<30) and thus further research is required. A recent metagenome wide 173 
association study from 218 individuals with atherosclerosis and 187 healthy controls 174 
observed that the gut microbiome deviates from a healthy status by an increase in the relative 175 
abundance of Enterobacteriaceae (including Escherichia coli, Enterobacter aerogenes and 176 
Klebsiella spp.) and Streptococcus spp (Table 1). Functionally, this impacts metabolism and 177 
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transport of molecules such as TMAO (64). These data suggest that the gut microbiome may 178 




Carotid atherosclerosis is linked to an increased risk of cardiovascular events such as stroke 183 
and ACS (40). Stroke is divided into two categories; ischemic stroke which occurs as a result 184 
of a blockage in a blood vessel supplying blood to the brain and haemorrhagic stroke, 185 
occurring from the rupture of a weakened blood vessel in the brain (6). Ischemic stroke 186 
accounts for 70 – 80% of all strokes (6). There is a bidirectional relationship between the 187 
brain and gut microbiota via vagus nerve activity and the enteric nervous system (26). During 188 
ischemic stroke, the brain produces molecules which signal damage, including damage 189 
associated molecular proteins and cytokines. The damage associated molecular proteins and 190 
cytokines produced in ischemic brain tissue are released into the circulation and 191 
communicate with immune and lymphoid organs leading to systemic inflammatory and 192 
immune responses (26). The gut will also release cytokines and gut inflammatory and 193 
immune cells will travel to the site of brain injury.  194 
 195 
After ischemic or haemorrhagic stroke, 50% of patients experience gastro intestinal issues, 196 
including gut microbiota dysbiosis, “leaky” gut, increased gut motility, disorganization and 197 
gut haemorrhage (169) as well as a reduced diversity and composition of the gut microbiota 198 
(173). As a result, intestinal inflammatory and immune responses are triggered (137). These 199 
patients have increased mortality rates and worsening neurological function with poor 200 
outcomes. This altered immune homeostasis largely occurs due to the gut microbiota’s role in 201 
communicating with intestinal epithelial cells, dendritic cells, B and T lymphocytes, 202 
mononuclear phagocytes and innate lymphoid cells (67). Zeng and colleagues investigated 203 
the association of the gut microbiome with high and low risk stroke and noted enrichment in 204 
opportunistic pathogens (e.g. Enterobacteriaceae and Veillonellaceae) and depleted 205 
abundance of butyrate producing bacteria (e.g. Lachnospiraceae and Ruminococcaceae) with 206 
reduced faecal butyrate levels in patients with a high risk of stroke (179). Many aspects of gut 207 
microbiota dysbiosis and modulation of inflammatory and immune responses have been 208 
implicated in stroke. However, what these effects signify in reality for stroke therapy remains 209 
to be investigated.  210 
 211 
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Coronary arteries  212 
 213 
Coronary artery disease (CAD) involves a narrowing of the coronary arteries supplying blood 214 
to the heart due to plaque build-up, thereby reducing blood flow. Atherosclerosis is the main 215 
pathophysiological basis of CAD. A small study found CAD patients had alterations in the 216 
gut microbiota, including an increase in Lactobacillales (from Firmicutes phylum and 217 
consisting of the genera Lactobacillus, Streptococcus and Enterococcus) whereas the phylum 218 
Bacteroidetes (composed of the genera Bacteroides and Prevotella) was reduced (42). 219 
Bacteroides fragilis promotes regulatory T-cell function in mucosal T-cell homeostasis (99). 220 
A recent study in CAD revealed a decreased microbial diversity and composition, as reflected 221 
by enrichment in Esherichia/Shigella and Enterococcus, while Faecalibacterium, 222 
Subdoligranulum, Roseburia and Eubacterium rectale were depleted (180). Faecalibacterium 223 
has an important anti-inflammatory role (89, 93), while Roseburia are important for SCFA 224 
production which potentially depletes energy supply for intestinal cells thus negatively 225 
affecting the  gut barrier (54, 76). In atheromatous plaques of patients with CAD, there was 226 
an enhanced bacterial diversity of Staphylococcus species, Proteus vulgaris, Klebsiella 227 
pneumoniae and Streptococcus sp. Although, there was a predominant bacterial signature in 228 
these plaques, it is not proof that the gut microbiota plays a causal role in atherosclerosis. 229 
Instead it has been suggested that the presence of the bacteria could contribute to 230 
atherosclerosis development and/or progression (107). 231 
 232 
ACS refers to a group of conditions including, unstable angina and acute myocardial 233 
infarction, and is usually characterised by a reduced blood flow to the heart muscle usually 234 
due to blockage (44). ACS is associated with inflammation, which plays a role in its 235 
pathogenesis. Evidence suggests that microbial dysbiosis may have an impact on several 236 
inflammatory or immune disorders via activating proinflammatory responses. Indeed, 237 
bacterial DNA was present on epicardial adipose tissue obtained during coronary artery 238 
bypass grafting in patients with ACS. This suggests that the epicardial adipose tissue 239 
environment is susceptible to microbial colonization, stimulating proinflammatory responses 240 
involved in vascular inflammation and plaque formation and instability. However, there is 241 
agreement that further research is warranted to provide more clarity to this important area   242 
(111).  243 
 244 
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Abdominal aortic aneurysm 245 
 246 
Abdominal aortic aneurysm (AAA) is a localised swelling of the walls of the abdominal 247 
aorta, the rupture of which can be fatal. Pathogenesis of AAA includes complex 248 
inflammatory pathways, extracellular matrix disruption, inflammation, thrombosis, 249 
haemodynamic forces and associated signalling molecules (58). Atherosclerosis is an 250 
important and independent risk factor for AAA (155) as patients with AAA frequently have 251 
atherosclerosis and there is an association of coronary heart disease and peripheral artery 252 
disease with AAA (57). An investigation of atherosclerotic plaques from vascular biopsies in 253 
patients with vascular diseases (including AAA), with and without chronic periodontitis, 254 
detected bacterial DNA in 95%, with most biopsies comprising DNA from multiple bacterial 255 
species (5). This reinforces recent findings that suggest more than one bacterial species are 256 
involved with CVD (41, 91). Although finding bacterial DNA in atherosclerotic plaques is 257 
well established, it is not clear whether an infection initiates or promotes its formation. 258 
Animal models have identified microorganisms such as 259 
Aggregatibacter actinomycetemcomitans, Helicobacter pylori, Chlamydophila perfringens 260 
and Porphyromonas gingivalis, which may contribute to increasing lesion areas in 261 
atherosclerosis (120). However, further research and validation in humans is required.  262 
In addition, gut microbiota function is affected by surgical abdominal aortic repair, which 263 
involves aortic clamping and can result in negative changes in intestinal permeability, which 264 
may also contribute to disease progression (109).  265 
 266 
Peripheral artery disease and mesenteric ischemia 267 
 268 
Peripheral artery disease (PAD) is characterised by reduced blood flow to the periphery, is a 269 
common consequence of systemic atherosclerosis and is associated with significantly higher 270 
risks of cardiovascular mortality. In patients with stable PAD, elevated plasma TMAO, a 271 
proatherogenic gut microbiota metabolite, was found to be a significant predictor of 5 year 272 
all-cause mortality risk, independent of traditional risk factors (131).  273 
 274 
Mesenteric ischemia occurs as a result of reduced blood supply to the mesenteries supplying 275 
the small intestine. The gut microbiome plays a key role in mesenteric ischemia via Toll-like 276 
receptors (TLR) which recognise constituent molecules of bacteria and contribute to 277 
maintenance of the intestinal environment by playing a key role in the innate immune system 278 
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(103). The TLR signalling pathway, specifically TLR2 and TLR4, activate inflammatory 279 
responses, such as the release of tumour necrosis factor-α. Oxidative stress caused by reactive 280 
oxygen species and free radicals, the source of which are neutrophils and macrophages, also 281 
affect the intestine during ischemia (103). Neutrophils and macrophages release reactive 282 
oxygen species and free radicals to sterilize invading bacteria, however, excess production 283 
can cause local tissue injury (103). Prevention of oxidative stress is useful for treatment of 284 
mesenteric ischemia. Previous studies showed heme oxygenase-1 plays a protective role in 285 
mesenteric ischemia and reperfusion, by preventing oxidation (85, 168). 286 
Gut microbiome metabolites  287 
 288 
  Trimethylamine-N-oxide  289 
 290 
The gut microbiota is known to be involved in the synthesis of proatherogenic metabolites, 291 
namely TMAO (Figure 3) (100). The breakdown of dietary substances rich in 292 
phosphatidylcholine, choline or carnitine (from red meat, fish and eggs) forms 293 
trimethylamine (TMA), the precursor to TMAO (84). TMA is absorbed in the intestine and 294 
converted via the hepatic enzyme flavin monooxygenase 3 to TMAO, a plasma metabolite 295 
released into the bloodstream and eventually cleared by the kidneys (76, 178). TMAO is a 296 
biologically active molecule and has been shown to be a predictor of ACS, stroke and death, 297 
likely through a proatherogenic pathway (74, 84, 178). When mice were supplemented with 298 
chronic dietary L-carnitine, there was an alteration in caecal microbial composition and 299 
increased synthesis of TMA and TMAO and enhanced atherosclerosis, however, this was not 300 
seen when intestinal microbiota was concurrently suppressed (74). In fact, mice with intact 301 
gut microbiota had a reduction in in vivo reverse cholesterol transport when supplemented 302 
with either carnitine or choline (74), reinforcing the role of the gut microbiota in promoting 303 
atherosclerosis  via the metabolism of L-carnitine, found in red meat. Evidence shows that 304 
individuals at higher risk for stroke and CVD have elevated TMAO levels as well as TMAO 305 
precursors (178). This was further reinforced when plaque progression and atherogenesis was 306 
promoted in apolipoprotein E knockout (ApoE-/- ) mice who were administered TMAO 307 
precursors or TMAO (55). Similarly, the administration of 3,3-dimethyl-1-butanol, a TMA 308 
inhibitor prevented cardiac dysfunction caused by a high sugar and high fat western diet (30).  309 
 310 
Studies have demonstrated a correlation between gut microbiota metabolism of TMAO and 311 
risk of CVD (74, 84, 147, 148, 165), with a recent meta-analysis revealing a 67% increased 312 
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risk of developing CVD with high TMAO levels. Furthermore, for every 10 µmol/L increase 313 
in TMAO, there was a 7.6% increase in all-cause mortality (127). TMAO enhances 314 
atherosclerosis via vascular inflammation, monocyte endothelial cell interactions and 315 
endothelial dysfunction as well as stimulating foam cell formation and atherosclerotic plaque 316 
progression (92, 130, 142). TMAO has been shown to activate inflammatory pathways within 317 
the vasculature, leading to leukocyte activation and atherosclerosis (130). TMAO levels were 318 
also elevated in individuals presenting with ACS and showed a dose-dependent relationship 319 
between increased risk of major adverse cardiac events and long-term mortality (84). TMAO 320 
has also been shown to play a role in promoting platelet hyperresponsiveness and thrombosis 321 
potential (181). TMAO acts to promote platelet reactivity through stimulus dependent 322 
calcium signalling, thereby increasing the risk of incident thrombotic events (181, 182). 323 
ApoE-/- mice with TMAO supplemented in their diet had enhanced aortic lesions (165). 324 
Human studies have also reinforced the role of TMAO in CVD. In a prospective, 325 
observational study of heart failure, stable CAD and healthy subjects, plasma TMAO, choline 326 
and betaine were elevated in chronic HF patients compared to controls (156). Similarly, in 327 
myocardial infarction patients, TMAO independently predicted death at 2 years [292 events, 328 
hazard ratio 1.21 (95% CI,  1.03-1.43, P = 0.023)] (143). A study by Tang and colleagues 329 
revealed a correlation between elevated TMAO levels and an increased risk of major adverse 330 
cardiac events (148).  331 
 332 
Bile Acid  333 
 334 
BAs are synthesised from cholesterol in the liver in a multistep processes involving several 335 
enzymes and are vital in the absorption of dietary fats in the intestine (78).  336 
Primary BAs are secreted into the duodenum and play a role in emulsifying lipid-soluble 337 
dietary substances and vitamins to facilitate digestion and absorption (176). Other features of 338 
BAs include their strong microbial activity (176) and their function as signalling molecules, 339 
acting as ligands for nuclear receptors, thus effecting metabolism. An example is the 340 
activation of the ‘Farnesoid-X-receptor’ (FXR), which supresses the action of cholesterol 7 341 
alpha-hydroxylase enzyme, which is important in the formation of primary BAs from its 342 
cholesterol precursor (78). 343 
 344 
In the intestine, gut microbiota modify primary BAs via bacterial salt hydrolase activity, 345 
which remove the -OH groups, turning them into secondary BAs (167). Primary BAs are 346 
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toxic to bacteria, hence making the BA more insoluble provide bacteria with a mechanism to 347 
reduce toxicity. Further modification of BAs by the gut microbiota may occur before being 348 
returned to the liver for re-conjugation and return to circulation (122). BAs are a vital 349 
pathway for cholesterol elimination via excretion in faeces, thereby decreasing circulating 350 
cholesterol levels and risk of plaque build-up (78). The gut microbiome can decrease BA 351 
synthesis rate, thus increasing the plasma levels of LDL and increasing the risk of 352 
atherosclerosis (126).  353 
 354 
Short chain fatty acid  355 
 356 
Short chain fatty acids such as acetate, butyrate and propionate are produced as a result of the 357 
fermentation of indigestible dietary fibres in the gut by the microbiota (47). They are straight 358 
chain saturated fatty acids composed of less than six carbon atoms (13). SCFA can either be 359 
absorbed via the gut epithelium to participate in various physiological processes or excreted 360 
in faeces (140). Butyrate is usually the primary source of energy for colonocytes (59), 361 
however SCFA may also have an anti-inflammatory role as well as effecting various other 362 
metabolic pathways including lipid metabolism and gluconeogenesis (13). Other SCFA such 363 
as acetate and propionate enter the portal circulation and are metabolised by the liver, or 364 
released into systemic circulation where they are able to bind to vascular endothelium SCFA 365 
receptors to influence cardiometabolic health (35). To prevent high concentrations of SCFA 366 
in blood, butyrate and propionate are cleared through the portal circulation (15). Increased 367 
faecal SCFA levels have been shown to be associated with decreased gut microbiota 368 
diversity, higher gut permeability, systemic inflammation, plasma glucose levels, 369 
dyslipidaemia, obesity and hypertension even after adjustment for confounders including 370 
diet, total calories and physical activity (33). Although they have very important regulatory 371 
roles, they also have quantitative roles as catabolic or anabolic substrates for the formation of 372 
glucose, cholesterol and lipid metabolism (35). 373 
 374 
SCFAs have been shown to exert a positive effect on modulating appetite, obesity and 375 
colonic inflammation (34, 49, 51). Despite this, elevated faecal SCFA have been associated 376 
with the metabolic syndrome, a risk factor for CVD (46, 151). This was demonstrated in 377 
TLR5 knock out mice, where microbiota dysbiosis generated uncontrolled prolonged 378 
production of SCFA and promoted development of the metabolic syndrome (136). TLR5 is a 379 
flagellin receptor required for gut microbiota homeostasis. In a study where rats were fed a 380 
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high fat diet, there was a positive correlation between obesity and the altered abundances of 381 
Phascolarctobacterium, Proteus mirabilis and Veillonellaceae, producers of propionate and 382 
acetate (79). Dysregulation of SCFA production has recently been suggested to also be a 383 
trigger in the aetiology of diabetes in two independent human studies (125, 154). Since SCFA 384 
energy is harvested from indigestible fibre, and they can enter the tricarboxylic acid cycle 385 
(which also regulates lipogenesis), in hypercaloric diets, an overproduction of SCFAs could 386 
result in an undesirable effect. 387 
Gut dysbiosis – links to inflammation and dyslipidaemia 388 
 389 
Atherosclerosis is considered a state of chronic inflammation coupled with lipid 390 
accumulation in the vessel walls. Systemic activation of the innate immune response as well 391 
as within and around the atherosclerotic plaque may enhance plaque progression and rupture. 392 
The gut microbiome enhances low grade inflammation in the gut, allowing entry of bacteria 393 
and their products into the circulation, triggering chronic inflammation (75). Associations 394 
between markers of systemic inflammation including C-reactive protein, interleukin-6 and 8 395 
and tumour necrosis factor- have been described in humans previously (19). Immune cells 396 
within coronary and carotid plaques of patients with ACS, have been shown to produce 397 
antibodies against gut microbial produced antigens (Klebsiella and Proteus strains) (22). 398 
Atherosclerotic plaques have their own microbial communities, similar in makeup to the oral 399 
cavity and gut (66, 77). However, a recent study has reported no association between 400 
atherosclerotic plaque microbial composition and clinical characteristics, contrasting with 401 
previous studies (86). These differences in results may be due to several reasons including 402 
differing methodologies, differences in population studied as well as population size and diet. 403 
As such, further research is highly warranted in this field. Hyperlipidemic ApoE-/- knockout 404 
mice exposed to nasal vaccination of outer membrane protein of Porphyromonas gingivalis, a 405 
gram negative oral cavity bacteria, had reduced atherosclerotic plaques and lower circulating 406 
levels of inflammatory cytokines (124).  407 
 408 
Dyslipidaemia refers to defects in lipid metabolism, where there is an elevation of plasma 409 
cholesterol, low-density lipoprotein-c, triglycerides or both, or a reduction of high-density 410 
lipoprotein cholesterol-c levels (97). Lipid levels are in part influenced by genetics, however, 411 
are also affected by dietary fat intake, exercise, smoking and alcohol consumption. There is 412 
extensive evidence from animal studies, clinical trials and observational epidemiological 413 
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studies that outline the causal role of LDL-C in atherosclerosis. Reduction of LDL-C lowers  414 
relative risk of major cardiovascular events (116) while HLD-C is inversely associated with 415 
risk of coronary heart disease (37). Additionally, the gut microbiome has been positively 416 
correlated with lipid and fatty acid metabolism and insulin resistance (14). The human gut is 417 
incapable of digesting complex carbohydrates in the form of dietary fibre, thus, it is the 418 
specific anaerobic gut bacteria that take on this role via fermentation, to produce SCFA. 419 
SCFA are involved in host energy metabolism, regulate intestinal immunity as well as 420 
influencing lipid and cholesterol metabolism (36). Host energy homeostasis is mediated by 421 
ligand/SCFA interaction with G protein-coupled receptors such as GPR41, expressed 422 
primarily in adipose tissue and GPR43, highest levels found in immune cells (17). GPR41 is 423 
activated by propionate followed by butyrate and acetate while GPR43 is activated by all 424 
three SCFAs at a similar rate (17). Both GPR41 and GPR43 proteins have been found in 425 
human colonic tissue (150), white adipose tissue (4), liver and skeletal muscle (17), 426 
suggesting that SCFAs may also have an effect on energy metabolism in peripheral tissues. 427 
Peptide YY, a gut hormone released postprandially in proportion to the calorie content of a 428 
meal and glucagon-like peptide-1 found on beta cells of the pancreas also maintain host 429 
energy balance, mainly by appetite reduction and promoting insulin secretion respectively. 430 
(9). Thus, it is expected that SCFA overproduction and/or different SCFA profiles can have 431 
an impact in metabolic homeostasis in the host (129). 432 
 433 
SCFA are also able to mediate fatty acid synthesis and oxidation and lipolysis via peroxisome 434 
proliferator-activated receptors, which have roles in carbohydrate, protein and lipid 435 
metabolism and tumorigenesis (23). As a result, there is an increase in lipolysis and beta 436 
oxidation, thus reducing lipid levels and circulating free fatty acids (24, 34). Apart from 437 
SCFA, the gut microbiome can influence lipid levels via the actions of conjugated linoleic 438 
acids (CLAs) and BA. Conjugated linoleic acids are produced by Bifidobacteria, Roseburia 439 
and Lactobacillus from omega-3 rich dietary sources (106). CLAs influence lipid metabolism 440 
by promoting SCFA producing bacteria, creating a cycle of peroxisome proliferator-activated 441 
receptor activation (29). BAs modulate hepatic and systemic lipid and glucose metabolism 442 
via the FXR (78, 123) or TGR5 (Takeda G protein coupled receptor) (72) receptors. FXR is 443 
an important BA receptor, primarily expressed in the liver and intestines, both it and TGR5 444 
plays a major role in carbohydrate and lipid metabolism, specifically, promoting glycogen 445 
synthesis and inhibiting gluconeogenesis (28). TGR5 is expressed in brown adipose tissue 446 
and muscle, when activated by BAs it promotes glucagon-like peptide-1 release, improving 447 
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liver and pancreatic function and enhanced glucose tolerance (152) as well as attenuating diet 448 
induced obesity (152). 449 
Microbiota – targeted therapies  450 
 451 
In recent years many studies have shown that the composition and diversity of gut microbiota 452 
can be beneficially altered by diet, prebiotics, probiotics, and faecal transplantation, to confer 453 




Protein, lipids and carbohydrates are macronutrients which compose the majority of the 458 
human diet (117). Dietary habits can influence gut microbiota composition which in turn 459 
modulates host health via digestion and absorption of nutrients (127). Microbiota bio-460 
transform dietary substances and synthesise metabolites which travel in the bloodstream to 461 
have distal effects on host metabolism and health (31). Reciprocally, diet composition can 462 
modulate the composition and function of the gut microbiome (121). Diet provides one of the 463 
simplest and easiest ways to modify the microbiome for therapeutic intervention (171). 464 
Components such as macronutrients, fibre, polyphenols, prebiotics and probiotics play a 465 
crucial role in shaping the gut microbiome, thereby influencing the production and release of 466 
gut microbiome metabolites, such as SCFAs (31).  467 
 468 
A study linking long term dietary patterns with gut microbial enterotypes demonstrated that 469 
intake of animal protein, amino acids and saturated fats were associated with the Bacteroides 470 
enterotype (171). In contrast, the Prevotella enterotype was low in these groups but high for 471 
carbohydrates and simple sugars. Vegetarians had an enrichment in the Prevotella enterotype. 472 
These dietary associations were similar in another study comparing the microbiome of 473 
European and Burkina Faso children (32). The microbiome of the European children was 474 
dominated by Bacteroides associated with the high protein and fat typical of a Western diet. 475 
Conversely, the Burkina Faso children’s microbiome was the Prevotella enterotype as 476 
characterised by their typical high carbohydrate and low animal protein diet.  477 
 478 
A diet high in vegetables, fruits, grains and legumes and low in red meats and processed 479 
carbohydrates – known as the Mediterranean diet, is beneficial in the prevention of CVD 480 
(39). This is due to the presence of antioxidants, nitrate and fibre as well as low 481 
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saturated/trans fatty acids, sodium and phosphate in this diet. This is likely to cause a 482 
reduction in oxidative stress and inflammation, enhanced antioxidant properties and nitric 483 
oxide bioavailability and thus modulation of gut microbiota to improve vascular and cardiac 484 
function (71). In contrast to the Mediterranean diet, the Western diet, high in saturated fat, is 485 
known to increase CVD risk by decreasing gut microbiota diversity and commensal bacteria, 486 
such as Bifidobacterium (10).  487 
 488 
Currently, there is a clear link between the diet and gut microbiome, such that the gut 489 
microbiota profile is different between various diets and geographic regions. However, there 490 
is still a substantial gap in our understanding of exactly how our diet modulates the gut 491 
microbiome and in turn the consequence of the gut microbiota in modulating host health. 492 
Further investigations are required as diet provides a low cost and easily manageable strategy 493 




Polyphenols are a large class of aromatic compounds found in plant-based beverages and 498 
foods such as apples, berries, citrus, cocoa, tea and coffee (170). There is substantial evidence 499 
that a polyphenol rich diet has cardioprotective and anti-diabetic properties (2, 65, 80, 110, 500 
174). Once ingested, polyphenols are broken down, metabolised and absorbed through the 501 
role of  the gut microbiota (170). Some polyphenols are affected by pH and change in 502 
chemical structure thus affecting their bioactivity (45). In addition, many polyphenols 503 
undergo hydrolysis via intestinal brush border or microbial enzymes. They may also undergo 504 
glucuronidation, methylation and sulfation during intestinal absorption and liver passage 505 
(94). There is extensive metabolism of polyphenols by the gut bacteria which will affect their 506 
bioavailability and bioactivity (132).  507 
 508 
Short term human studies, involving the consumption of tart cherry juice rich in polyphenols, 509 
namely anthocyanins and flavonoids, demonstrated the ability of the gut microbiota to 510 
ferment polyphenols to influence polyphenol metabolites (98). In the group (n=5) of 511 
individuals with a high Bacteroides group from low carbohydrate and fibre consumption, 512 
drinking tart cherry juice decreased the levels of Bacteroides and increased fermentative 513 
Firmicutes. In the low Bacteroides group (n=5), there was an increase in Bacteroides and 514 
Bifidobacterium (due to polyphenol availability) and a decrease in Firmicutes. Anthocyanins 515 
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act as antiplatelet agents in atherosclerosis and CVD prevention, while also inducing nitric 516 
oxide formation in the blood vessels, promoting vasodilation (53). Furthermore, individuals 517 
consuming a more Western influenced diet, may have a reduced ability to metabolise 518 
polyphenols, thus reducing their bioavailability, bioactivity and hence any potential health 519 
benefits (98). Similarly, the intake of polyphenols via grape and red wine demonstrated the 520 
gut microbiota’s ability to promote beneficial microbial communities to enhance host health 521 
(104).  522 
 523 
Quercetin is a member of the flavonoid family, a subclass of polyphenols and is thought to 524 
have antioxidant and anti-inflammatory properties (16, 153). Quercetin administered as a 525 
treatment to mice fed a high fat sucrose diet, modified the gut microbiota and attenuated the 526 
increase of the Firmicutes/Bacteroidetes ratio (43). Generally, gut microbiota associated with 527 
obesity has been associated with a reduced Bacteroidetes to Firmicutes ratio (82, 115). 528 
Similarly, quercetin reduced the abundance of Erysiepelotrichaceae on a family level and at 529 
the genus level Bacillus, which have been related to the Western diet and weight gain (158). 530 
Furthermore, it significantly altered the composition of several bacterial species, increasing 531 
the relative abundances of Bacteroides vulgatus and Akkermansia muciniphila which have 532 
been inversely associated with obesity, while reducing Eubacterium cylindroides and 533 
Bilophilia wadsworthia, associated with diet-induced obesity (12, 43, 160). A metagenomic 534 
study in mice that developed obesity via a high fat sucrose diet demonstrated that the 535 
microbiome of high fat sucrose diet fed mice was rich in genes which are associated with 536 
sugar uptake for intestinal bacteria (158). Moreover, quercetin improved basal insulin levels 537 
(43). This suggests a modulating role of quercetin in altering bacterial profiles to attenuate or 538 
improve obesity.  539 
 540 
Specific dietary polyphenols have been shown to have beneficial effects on vascular function 541 
and attenuation of atherosclerosis. Quercetin and its metabolites have been shown to 542 
upregulate adenosine monophosphate-activated protein kinase (AMPK) expression (133). 543 
AMPK is an enzyme that plays a role in cellular energy homeostasis and fatty acid oxidation. 544 
Quercetin and its metabolites have been shown to protect blood vessels against endothelial 545 
dysfunction in intact mouse aortic rings (133). Inhibition of AMPK diminished the positive 546 
effects. In human aortic endothelial cells, quercetin and its metabolites induced AMPK and 547 
endothelial nitric oxide synthase activation, leading to an increase in nitric oxide, a potent 548 
vasodilator (133). In another study, quercetin and theaflavin significantly attenuated 549 
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atherosclerotic lesion size in both the aortic sinus and thoracic aorta of ApoE -/- mice through 550 
reduction of inflammation, improving nitric oxide bioavailability and inducing heme 551 
oxygenase-1, an enzyme that plays a crucial role in prevention of vascular inflammation (88). 552 
In mice fed a high fat diet, quercetin protects against oxidant-induced endothelial dysfunction 553 
and ApoE -/- mice against atherosclerosis (134). These results provide further reinforcement 554 
and support for the cardioprotective effects of quercetin, a dietary polyphenol. 555 
 556 
Dietary polyphenols are increasingly recognised as a novel strategy in the potential 557 
prevention and treatment of several diseases including CVD and type 2 diabetes. This is 558 
explained by the bidirectional relationship which exists between polyphenols and the gut 559 
microbiota to influence factors such as blood pressure, endothelial function, insulin 560 
sensitivity, thereby promoting cardioprotective and antidiabetic effects. Polyphenols 561 
supplemented in the diet at high bioavailability, may improve gut microbiota modulation of 562 
CVD and obesity. However, it is recognised that more targeted research activities are still 563 
required to resolve the remaining unanswered issues.  564 
 565 
Prebiotics, probiotics and synbiotics  566 
 567 
Prebiotics are nondigestible food ingredients which promote gut microbiota composition and 568 
activity with positive effects on the host (56). They  are usually obtained in the diet from 569 
fibre rich foods (63) and commonly screened for their ability to increase bifidobacterial 570 
numbers. A high fibre diet has been reported to modify the gut microbiota to increase acetate 571 
producing bacteria, which contributed to a reduction in gut microbiota dysbiosis and offered 572 
cardioprotective effects (95). Acetate is associated with regulating many pathways and genes 573 
involved in CVD, such as transcription factor Egr1, a regulator of CVD through 574 
inflammation, cardiac fibrosis and hypertrophy (95). In contrast, mice fed an atherogenic 575 
Paigen diet (mimics inflammation in lean subjects) high in saturated fat and low in fibre, led 576 
to the development of the metabolic syndrome including hyperinsulinemia, steatohepatitis, 577 
hyperglycaemia and inflammatory infiltration into the aorta, contributing to the development 578 
of atherosclerosis via the gut microbiota (112).  579 
 580 
Dietary supplementation with an inulin/fructooligosaccharides (FOS) mixture (10 g/day) 581 
stimulated Bifidobacterium increase (114) while another study demonstrated the increase in 582 
Bifidobacterium following FOS supplementation (149). Beta glucan is another prebiotic 583 
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shown to have an influence on lowering cholesterol levels and maintaining blood glucose 584 
homeostasis. A study where beta glucan was administered as a dietary intervention over a 585 
period of 2 months demonstrated a significant decrease in low density lipoprotein and total 586 
cholesterol levels as well as improving endothelial function in healthy individuals thus 587 
providing cardioprotective effects, mainly through beneficial SCFA production via the gut 588 
microbiome (63). In a recent study involving C57BL6 mice, we demonstrated in a long term 589 
dietary supplementation with a combination of isoquercetin, a polyphenol and inulin, a 590 
prebiotic, that the development of metabolic syndrome was prevented (144). Compared to 591 
mice fed a high fat diet, the mice supplemented with isoquercetin and inulin had attenuated 592 
weight gain, improved glucose tolerance, insulin sensitivity, as well as improvements in the 593 
gut microbiota composition and functionality and SCFA production (144). Inulin was found 594 
to increase faecal SCFA levels of acetate, butyrate and propionate. Animal studies have also 595 
demonstrated arabinoxylans as a potential prebiotic due to its role in promoting 596 
bifidobacterial and propionate synthesis with beneficial effects on lipid and cholesterol 597 
accumulation (105, 159). In humans arabinoxylanoligosaccharides supplemented in the diet 598 
increased bacterial populations and butyrate concentrations in faeces (162). Taken together, 599 
these findings reinforce the importance of diet in the prevention of CVD and the metabolic 600 
syndrome. 601 
 602 
Live bacteria, known as probiotics, can be ingested for maintaining or promoting gut 603 
microbiota composition (146). Most probiotic products are likely to contain beneficial 604 
Bifidobacteria, Lactobacilli, Lactococci and Streptococci (7). Probiotics depending on their 605 
nature,  may inhibit the overgrowth of pathogenic bacteria, stimulates the immune system, 606 
modulates pH levels and prevent inflammation (177). Probiotics can improve host 607 
metabolism by stimulating digestive enzyme activity and inhibiting bacterial enzyme activity 608 
and production of ammonia. Lactobacillus and Bifidobacterium are beneficial as they 609 
improve intestinal barrier function and play a protective role in inflammatory disease (163, 610 
172) by modulating inflammatory and proinflammatory cytokines (such as tumor necrosis 611 
factor-α), which may delay and/or improve CVD (62). Probiotics are designed to exert their 612 
beneficial effects by restoring the normal composition of microbiota by producing SCFAs 613 
(27). Akkermansia muciniphila is also known for its probiotic properties and has been 614 
demonstrated to be linked with glucose, insulin and leptin which are involved in lipid and 615 
glucose metabolism (128). It is also an important modulator of mucus thickness and gut 616 
barrier integrity probably due to its close proximity in the mucus layer and closeness to 617 
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epithelial cells (108). In a randomized double-blind clinical trial, Lactobacillus plantarum, a 618 
probiotic, significantly reduced LDL-C and total cholesterol levels and inhibited 619 
atherosclerotic plaque formation in hypercholesterolaemic patients (50).  620 
 621 
The combination of prebiotics with probiotics for use is known as synbiotics. Synbiotics may 622 
further support the growth, survival and persistence of beneficial bacteria as a specific 623 
substrate is provided for fermentation by the bacteria (141). Several studies have 624 
demonstrated the potential benefits of synbiotics on the gut microbiota and immune functions 625 
in chickens (38, 101). In high fat diet mice, symbiotic intervention significantly reduced body 626 
weight gain and attenuated features of metabolic syndrome as well as restoring the gut 627 
microbial ecosystem structure and function(69).  628 
 629 
The studies discussed above have predominately investigated the effects of prebiotics, 630 
probiotics and synbiotics on risk factors for cardiovascular disease, such as inflammation, 631 
hypertension and effects on glucose and lipid metabolism, as opposed to investigating the 632 
direct benefit in atherosclerosis. However, given their beneficial effects on various CVD risk 633 
factors, further research investigating how these treatments affect development and 634 
progression of atherosclerosis is warranted.   635 
 636 
Selective TMAO inhibitors  637 
 638 
A recent study was successful in developing a mechanism- based inhibitor drug (3,3-639 
dimethyl-1-butanol), targeting major microbial TMA generating enzymes (CutC/D)  where a 640 
single oral dose caused a significant reduction in plasma TMAO levels for up to three days as 641 
well as reducing enhanced platelet responsiveness and thrombus formation induced by diet 642 
(118). This inhibitor is potent, time dependant, irreversible and did not affect other 643 
commensals’ normal functioning or observable toxicity. When dimethyl-1-butanol was given 644 
to atherosclerotic prone ApoE -/- mice on a choline- supplemented diet, plasma TMAO levels 645 
significantly reduced, macrophage cholesterol accumulation, foam cell formation and 646 
atherosclerotic lesion development were also reduced (166). Microbial protein pairs (CutC 647 
and CutD), encoded by genes of the choline utilisation gene cluster (cut) have been shown to 648 
support choline TMA lyase enzyme activity (96, 119). Current antiplatelet drugs and 649 
medication target mammalian enzymes and receptors and have the potential to cause bleeding 650 
(52). In contrast, inhibiting microbial generation of TMAO would not supress platelet 651 
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function and therefore, increase the risks of bleeding. This study (118) suggests the selective 652 
and nonlethal targeting of specific gut microbiome enzymes which are shown to be linked to 653 
disease, thus, limiting systemic exposure of the inhibitor in the host. There is growing 654 
evidence of the contributory role of the gut microbiota in health and disease, thus ‘medicating 655 
the microbiome’ is at the forefront of clinical potential and could become a common therapy 656 
in the future. The development of drugs which inhibit selective gut microbial catabolic 657 
pathways mechanistically linked with pathogenesis of disease should be further investigated 658 
as a potential therapy for CVD.  659 
 660 
Faecal microbiome transplant 661 
 662 
Faecal microbiome transplantation refers to the transfer of one’s own or a donor’s faecal 663 
sample to a receiver in order to restore gut microbiome dysbiosis and function (146). With 664 
more than 70% of gut bacteria colonising the large intestine, they are commonly represented 665 
in a stool sample (127). Currently, faecal transplantation is used for treating gastrointestinal 666 
disease, such as Clostridium difficile infection and inflammatory bowel diseases such as 667 
ulcerative colitis (146, 164). Several studies investigated faecal transplantation as a prospect 668 
in altering the gut microbiome as a potential therapy for metabolic syndrome and obesity (8, 669 
157). A study involving gut microbial infusion via a gastroduodenal tube in 9 obese and 9 670 
healthy Caucasian males revealed peripheral insulin sensitivity improved after 6 weeks post 671 
allogenic gut microbiota infusion (from lean donors) (161). In obese subjects there was a 672 
lower microbial diversity in faecal microbiota, with high levels of Bacteroidetes and reduced 673 
Clostridium levels compared to healthy controls. Upon allogenic gut microbial infusion, gut 674 
microbiota diversity significantly increased in the obese group, including butyrate producing 675 
bacteria Roseburia intestinalis which increased 2.5-fold. This suggests a regulating role of 676 
butyrate derived from gut microbiota metabolism causing an improvement in insulin 677 
sensitivity in obese Caucasian males. Butyrate has been suggested to prevent translocation of 678 
endotoxins derived from the gut microbiota, by promoting intestinal mucosa barrier function 679 
(25, 81), which has been associated with insulin resistance (25). Increased gut microbiota 680 
diversity has also been linked with improved insulin resistance (25). Recently, faecal 681 
transplantation from hypertensive mice to germ free mice have demonstrated that high blood 682 
pressure is transferrable (1, 70).  683 
 684 
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There is currently limited evidence on the role of faecal microbiome transplantation in 685 
relation to gut microbiota in human patients with CVD, prompting further research in this 686 
area in the future. There are also many methodologies and variation in processing, such as, 687 
donor choice and testing, faecal microbiome transplantation via upper gastrointestinal tract, 688 
enema or colonoscopy, short and long-term monitoring of patients for adverse effects as well 689 
as efficacy of treatment (21). These variations mean that faecal microbiome transplantation 690 
needs to be regulated before being offered as a suitable treatment option. The clinical use and 691 
consequence of faecal transplantation is further limited by news from a recent case involving 692 
the severe sepsis and death of two immunocompromised adults after receiving faecal 693 
transplantation containing multi-drug resistant organisms (as reported by the FDA). As such, 694 
the future use of faecal microbiome transplantation remains challenging. 695 
 696 
Future clinical impact of the gut microbiome on CVD 697 
 698 
There is mounting evidence that the gut microbiome contributes to both normal health and 699 
disease in the host. This provides a novel perspective with far reaching clinical impact. The 700 
approach to disease diagnosis, management, treatment and prevention is expanding. 701 
Metagenomic sequencing and analysis along with molecular and biochemical methodologies 702 
has advanced, allowing identification and characterisation of specific microbiome taxa and 703 
their associated metabolites in various samples. Although, on a mechanistic level, much 704 
remains to be elucidated. In the future, microbiome profiling of patients through metabolomic 705 
/biomarker analysis may be performed to determine the health of the individual, with possible 706 
guidance on dietary and lifestyle changes as an approach to targeted intervention. 707 
Furthermore, the use of faecal microbiome transplantation, prebiotics and probiotics to 708 
manipulate and alter the gut microbial ecology to produce beneficial metabolites to improve 709 
host health may provide an alternate adjunct therapy.  710 
Conclusion  711 
 712 
Microbiome-host interactions are now understood to be paramount in health and disease 713 
susceptibility. There is a mechanistic link between gut microbiota and physiological 714 
processes in the body that affect CVD risk. Furthermore, the gut microbiome is a key player 715 
at the intersection of diet and CVD via its role in metabolising dietary components and thus, 716 
the synthesis and release of important metabolites such as SCFA and TMAO. Current 717 
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literature provides evidence that there is a correlation between atherosclerosis and gut 718 
microbiome dysbiosis (Figure 4). This change in gut microbiome may contribute to adverse 719 
cardiac function resulting in an increase in morbidity and even death. However, it is not clear 720 
whether gut microbiome dysbiosis is a contributor and/or consequence of disease. Further 721 
research is required in order to characterise the microbiota in healthy individuals and those 722 
with CVD. Research into the roles of various metabolites such as SCFA, TMAO and BA and 723 
their mechanism of action is also highly warranted as they have been demonstrated to have a 724 
vital role in the modulation and influence of host health. As we gain a more comprehensive 725 
understanding of the role of the gut microbiota and their metabolites and exactly how they 726 
cause the progression and pathogenesis of disease, we may be able to develop advanced 727 
diagnostic strategies and potential therapeutic interventions to cater to a more personalised 728 
clinical care of patients in the future. Novel therapies including manipulating the diet and 729 
using newly designed prebiotic and probiotic options to treat CVD through modulating the 730 
gut microbiota and associated metabolites are all gaining traction. 731 
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Tables, Figures and Figure Legends 1261 
 1262 
Table 1: Summary of studies investigating associations between the gut microbiome and CVD.  1263 
Reference Method Number of 
subjects 
Disease status Main findings 
(121) 16S rRNA & 
metagenome 
sequencing  
N =1046 Plasma lipids, 
Glycaemic traits 
 
Microbiota predominantly shaped by 
non-genetic factors and explain  % 
variance in HDL, fasting glucose, 
obesity 
(64) Metagenome 
shotgun sequencing  
N =218 CVD 
N =187 controls 
Atherosclerosis In CVD, increased Enterobacteriaceae 
& Streptococcus  
(83) 16S rRNA  N =56 pre-
hypertensive 
N =99 hypertensive 
N =41 controls 
Hypertension  Reduced bacterial diversity 
Overgrowth of Prevotella/Klebsiella in 
prehypertension and hypertension 
compared to controls 
(61) qPCR N =179 CAD 
N =166 ACS 
N =119 controls 
CAD Aggregatibacter 
actinomycetemcomitans 
levels linked with risk for CAD 
(68) MEDUSA N =12 symptomatic 
atherosclerosis 
Atherosclerosis Collinsella genus higher in symptomatic 
AS 
Downloaded from www.physiology.org/journal/ajpheart at Univ Col Cork (143.239.102.069) on September 5, 2019.
Running Head: GUT MICROBIOME AND ATHEROSCLEROSIS 
  47




N =15 CVD 
N =15 controls 
Atherosclerosis Overgrowth of Veillonella and 
Streptococcus in atherosclerotic plaque 
samples 
16S rRNA: 16S ribosomal ribonucleic acid, HDL: High density lipoprotein, CVD: cardiovascular disease, qPCR: quantitative polymerase chain reaction, CAD: 1264 
coronary artery disease, ACS: acute coronary syndrome, MEDUSA: Metagenomic Data Utilization and Analysis. 1265 
 1266 




Figure 1: Relative distribution of the five main bacterial phyla found in the gut obtained 1268 
from the RDP (ribosomal database project) browser. Firmicutes and Bacteroidetes compose 1269 
65% and 30% of the gut respectively. Others include the remaining phyla: Spirochaetes, 1270 
Fusobacteria, Deferribacteres, Cyanobacteria, Planctomycetes, Lentisphaerae, TM7 and 1271 
Tenericutes. Adapted from (175).  1272 





Figure 2: Cardiovascular disease manifestations in which gut microbiota and their associated 1275 









Figure 3: Interactions between diet and the gut microbiota to form metabolites such as SCFA 1282 
and TMAO, which play a crucial role in host health and cardiovascular risk. CVD: 1283 
cardiovascular disease, FMO3: Flavin monooxygenase 3, GPCR: G protein coupled receptor, 1284 
PBA: primary bile acid, SBA: secondary bile acid, SCFA: short chain fatty acid, TMA: 1285 





























Figure 4: The complex relationship between dietary components ingested and other factors, 1312 
affecting the gut microbiota, whose composition then influences their functionality and 1313 
metabolite production and release. A disruption to which leads to dysbiosis, thereby affecting 1314 
host health and the progression and pathogenesis of various cardiovascular diseases in a 1315 
vicious cycle. ATP: Adenosine triphosphate, BA: bile acid, CO2: carbon dioxide, CH4: 1316 
methane, CVD: cardiovascular disease, H2S: hydrogen sulphide, PBA: primary bile acid, 1317 
ROS: reactive oxygen species, SBA: secondary bile acid, SCFA: short chain fatty acid, 1318 
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Figure 4: The complex relationship between dietary components ingested and other factors, 
affecting the gut microbiota, whose composition then influences their functionality and 
metabolite production and release. A disruption to which leads to dysbiosis, thereby affecting 
host health and the progression and pathogenesis of various cardiovascular diseases in a 
vicious cycle. ATP: Adenosine triphosphate, BA: bile acid, CO2: carbon dioxide, CH4: 
methane, CVD: cardiovascular disease, H2S: hydrogen sulphide, PBA: primary bile acid, 
ROS: reactive oxygen species, SBA: secondary bile acid, SCFA: short chain fatty acid, 
TMAO: Trimethylamine- N- oxide. 
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